<SEC-DOCUMENT>0001144204-19-040824.txt : 20191023
<SEC-HEADER>0001144204-19-040824.hdr.sgml : 20191023
<ACCEPTANCE-DATETIME>20190820162059
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0001144204-19-040824
CONFORMED SUBMISSION TYPE:	CORRESP
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20190820

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ABEONA THERAPEUTICS INC.
		CENTRAL INDEX KEY:			0000318306
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				830221517
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		CORRESP

	BUSINESS ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019
		BUSINESS PHONE:		646-813-4701

	MAIL ADDRESS:	
		STREET 1:		1330 AVENUE OF THE AMERICAS, 33RD FLOOR
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10019

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PLASMATECH BIOPHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20140922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ACCESS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19960209

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CHEMEX PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="tv528042_logo.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Christine Silverstein</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Abeona Therapeutics Inc.<BR>
1330 Avenue of the Americas, 33rd Floor<BR>
New York, NY 10019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">August 20, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>VIA EDGAR</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">United States Securities and Exchange Commission</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Division of Corporation Finance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Office of Healthcare &amp; Insurance</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">100 F Street, N.E.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%"><FONT STYLE="font-size: 10pt">Attention: </FONT></TD>
    <TD STYLE="width: 90%"><FONT STYLE="font-size: 10pt">Mary Mast</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Angela Connell</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt"><B>Re: </B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Abeona Therapeutics Inc. </B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Form 10-K for the Fiscal Year Ended December 31, 2018</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>Filed March 18, 2019</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt"><B>File No. 001-15771</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Abeona Therapeutics Inc. (the &ldquo;<B>Company</B>&rdquo;)
submits this letter in response to your letter dated August 5, 2019, relating to the above-referenced filing by the Company. Set
forth below in italics are the comments contained in the Staff&rsquo;s letter, together with the Company&rsquo;s responses. Capitalized
terms not defined herein should be given the meaning provided in the above-referenced filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Management&rsquo;s Discussion and Analysis of Financial Condition
and Results of Operations</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><U>Contractual Obligations, page 61</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD><I>You disclose that REGENXBIO is eligible to receive low double-digit royalties on net sales of products incorporating the
licensed intellectual property. Please revise your future filings to disclose the royalty rate or a range that does not exceed
a 10 point range. </I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"><B>Response</B>: In response to
the Staff&rsquo;s comment, our Form 10-Q for the quarter ended June 30, 2019 filed on August 9, 2019 discloses a range for the
royalty rate in the REGENXIO agreement that is smaller than 10 points. In addition, we will revise other future filings accordingly
as applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">1330
                                         Avenue of the Americas &ndash; Floor 33, New York, New York 10019</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Tel
                                         1-646-813-4707 &bull; www.abeonatherapeutics.com</FONT></P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>



<P STYLE="margin: 0; text-align: left">&nbsp;&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><IMG SRC="tv528042_logo.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD><I>Article XII of your Amended and Restated Bylaws filed as Exhibit 3.2 appears to contain a fee-shifting provision. Please
revise your future filings to disclose this provision in your Risk Factors section and where applicable, including the types of
actions subject to fee shifting, whether the company intends to apply the provision to claims under federal securities laws, the
ability of the shareholders to bring suit for claims arising under state law, and who is subject to the provision and who would
be allowed to recover (e.g., company, directors, officers, affiliates). In addition, disclose the level of recovery required by
the plaintiff to avoid payment and if you intend to interpret/apply such language as broadly as possible. In this regard, when
describing a Claiming party&rsquo;s obligation to pay if it &ldquo;does not obtain a judgment on the merits that substantially
achieves, in substance and amount, the full remedy sought by such Claiming Party&rdquo; please describe what would constitute such
a judgment. Please also describe the effect of the provision, such as possibly discouraging shareholder lawsuits that might otherwise
benefit the company and its shareholders. Finally, please discuss the validity of the provisions in Article XII of your Bylaws
in light of Section 109(b) of the Delaware General Corporation Law.</I></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><B>Response</B>: We are in the process of amending
our Bylaws to remove Article XII in its entirety, and will report the adoption of such amendment in a Current Report on Form 8-K
and file the amended and restated Bylaws in accordance with Item 601 of Regulation S-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If you have any questions regarding this
response letter or the Form 10-K, please contact our counsel, Morgan, Lewis &amp; Bockius LLP, by calling John J. Concannon III
at (617) 951-8874.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Remainder of page intentionally left
blank</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">1330
                                         Avenue of the Americas &ndash; Floor 33, New York, New York 10019</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Tel
                                         1-646-813-4707 &bull; www.abeonatherapeutics.com</FONT></P><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0; text-align: right">&nbsp;<IMG SRC="tv528042_logo.jpg" ALT=""></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">Very truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="padding-top: 10.7pt"><FONT STYLE="font-size: 10pt">ABEONA THERAPEUTICS INC.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">By:</P></TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">/s/ Christine Silverstein</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Christine Silverstein</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD COLSPAN="3"><FONT STYLE="font-size: 10pt">CC: &#9;John J. Concannon III, Esq., Morgan, Lewis &amp; Bockius LLP </FONT></TD></TR>
</TABLE>


<P STYLE="margin: 0; text-align: right"></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt"></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">1330 Avenue of the Americas &ndash; Floor 33, New York, New York 10019</FONT></P><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 8pt">Tel 1-646-813-4707 &bull; www.abeonatherapeutics.com</FONT></P><P STYLE="margin: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0in">&nbsp;</P>



<P STYLE="margin: 0; text-align: left">&nbsp;</P>

<P STYLE="margin: 0; text-align: left">&nbsp;</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tv528042_logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tv528042_logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !N 0P# 2(  A$! Q$!_\0
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M-1U.?5_%46A0KJ-I#"2;EGL5DM[E, E2S= 1D9[YKK(HHX(DBAC6.- %5$&
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M ("?TJO8QDFX2O;79HGVTHM<\;7TW3._HK&\5:V?#WAJ\U)55Y(E C5NA<D
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M8#2M(L]/$AD%M"L0<C&[ QG%9N<?8*'6]_P-%"7MW/I:WXERN TG_DM.N_\
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MP"\NWXFC16=_9"?\_M__ .!+4?V0G_/[?_\ @2U%H]_P"\NWXFC16=_9"?\
M/[?_ /@2U']D)_S^W_\ X$M1:/?\ O+M^)HT5G?V0G_/[?\ _@2U']D)_P _
MM_\ ^!+46CW_  "\NWXFC16=_9"?\_M__P"!+4?V0G_/[?\ _@2U%H]_P"\N
MWXFC16=_9"?\_M__ .!+4?V0G_/[?_\ @2U%H]_P"\NWXFC16=_9"?\ /[?_
M /@2U']D)_S^W_\ X$M1:/?\ O+M^)HT5G?V0G_/[?\ _@2U']D)_P _M_\
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CY(S@Y-69M/::=Y!?7<8;'R(X"CC''%*?([<N@X>T5^;4_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
